New study checks how well a targeted breast cancer drug works in russian patients
NCT ID NCT07281001
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study will look at medical records of 60 Russian patients with advanced HER2-positive breast cancer who have received trastuzumab deruxtecan. Researchers want to see how long the drug keeps cancer from growing and how safe it is. The goal is to understand how well this treatment works in real-world settings in Russia.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- trastuzumab deruxtecan
- What this could lead to
- If successful, this could confirm that trastuzumab deruxtecan is effective for Russian patients with advanced HER2+ breast cancer, supporting its use in this population.
- What could go wrong
- This is an observational study, not a controlled trial, so results may be less reliable. It is also small (60 people) and only looks back at existing data, which can have missing information.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Federal State Budgetary Institution "N.N. Blokhin National Medical Research Center of Oncology" оf the Ministry of Health of the Russian Federation
RECRUITINGMoscow, 115522, Russia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a triple drug combo shrink HER2-Positive breast tumors before surgery?
- Can a Two-Drug attack shrink Hard-to-Treat breast cancer?
- Can an extra radiation dose keep HER2+ breast cancer at bay?
- Can mapping tumor DNA unlock personalized breast cancer care?
- Can a drug cocktail cure metastatic breast cancer? a trial aims to find out
- Can less chemo be enough? a trial challenges standard treatment for HER2-Positive breast cancer